4//SEC Filing
Mazumdar Claire 4
Accession 0002034671-25-000009
CIK 0002023658other
Filed
Nov 24, 7:00 PM ET
Accepted
Nov 25, 6:40 PM ET
Size
8.9 KB
Accession
0002034671-25-000009
Insider Transaction Report
Form 4
Mazumdar Claire
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
2025-11-24$18.86/sh−41,163$776,429→ 309,892 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-24−41,163→ 236,107 totalExercise: $3.79Exp: 2033-08-08→ Common Stock (41,163 underlying) - Exercise/Conversion
Common Stock
2025-11-24$3.79/sh+41,163$156,000→ 351,055 total
Footnotes (3)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $18.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F3]The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.
Documents
Issuer
Bicara Therapeutics Inc.
CIK 0002023658
Entity typeother
Related Parties
1- filerCIK 0002034671
Filing Metadata
- Form type
- 4
- Filed
- Nov 24, 7:00 PM ET
- Accepted
- Nov 25, 6:40 PM ET
- Size
- 8.9 KB